News & Media

Amplyx laid out a promising path to a pivotal antifungal drug trial, and now Pfizer is scooping it all up in a buyout

Pfizer buys Amplyx to grow infectious disease pipeline

Pyxis debuts next-gen cancer ADCs from under Pfizer's wing

Artios, Novartis form cancer therapies collaboration

Novartis taps Artios for targets to enhance radioligand drugs

Five Investment Company Bargains

Pyxis follows Pfizer alliance with $152m fundraising for cancer pipeline

After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B

Arix leads USD152m Series B financing for Pyxis Oncology

Oncology startup to double size with $152M

Armed with Pfizer's ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs

Arix Bioscience leads US$152mln funding round for Pyxis Oncology

With ADC pipeline now a top priority, Pyxis adds $152M series B

Clean up with two deep value plays

New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech

Arix Bioscience reports FY20NAV up 62%

Arix Bioscience sees sharp uplift in net asset value in 2020

Arix Bioscience Shares Rally 5.4% as Net Asset Value Surges on VelosBio Sale to Merck

Arix Bioscience sees value rocket 62% as UK biotech scene booms

The Fight Against Fungi

Bargain shares for 2021

LSX London 2021 Biotech - Accelerating Innovation Through Early-Stage Investment

Biden administration – What can the healthcare industry expect?

Around the World in Venture Capital

David Stevenson: This is my portfolio for 2021

Exploit Arix Bioscience’s huge margin of safety

Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment

Why Tech trend is worth following beyond 2020

Arix Bioscience shares rise on collaboration deal with Merck KGaA

Arix Bioscience portfolio company Artios signs cancer collaboration deal with Merck KGaA worth up to $7bn

Latest takeovers focus on two specific groups of stocks

Deal-Making During A Pandemic And 2021 Expectations